Tri-luma is a drug owned by Galderma Laboratories Lp. It is protected by 4 US drug patents filed from 2013 to 2014. Out of these, 2 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 22, 2026. Details of Tri-luma's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7915243 | Topical skin care composition |
Mar, 2026
(1 year, 3 months from now) | Active |
| US7939516 | Topical skin care composition |
May, 2025
(4 months from now) | Active |
| US8653053 | Topical skin care composition |
Oct, 2022
(2 years ago) |
Expired
|
| US8247395 | Topical skin care composition |
Oct, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tri-luma's patents.
Latest Legal Activities on Tri-luma's Patents
Given below is the list of recent legal activities going on the following patents of Tri-luma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 08 Apr, 2024 | US8247395 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Nov, 2022 | US7939516 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2022 | US7915243 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Feb, 2020 | US8247395 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Oct, 2018 | US7939516 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Sep, 2018 | US7915243 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Aug, 2012 | US8247395 |
| Recordation of Patent Grant Mailed Critical | 21 Aug, 2012 | US8247395 |
| Issue Notification Mailed Critical | 01 Aug, 2012 | US8247395 |
| Dispatch to FDC | 23 Jul, 2012 | US8247395 |
US patents provide insights into the exclusivity only within the United States, but Tri-luma is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tri-luma's family patents as well as insights into ongoing legal events on those patents.
Tri-luma's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tri-luma's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 22, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tri-luma Generics:
There are no approved generic versions for Tri-luma as of now.
About Tri-luma
Tri-Luma is a drug owned by Galderma Laboratories Lp. Tri-Luma uses Fluocinolone Acetonide; Hydroquinone; Tretinoin as an active ingredient. Tri-Luma was launched by Galderma Labs Lp in 2002.
Approval Date:
Tri-luma was approved by FDA for market use on 18 January, 2002.
Active Ingredient:
Tri-luma uses Fluocinolone Acetonide; Hydroquinone; Tretinoin as the active ingredient. Check out other Drugs and Companies using Fluocinolone Acetonide; Hydroquinone; Tretinoin ingredient
Dosage:
Tri-luma is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.01%;4%;0.05% | CREAM | Prescription | TOPICAL |